![institutions-DFCI-Logo-500px-rgb[2]20221027132117.jpg](/images/institutions/logos/DFCI-Logo-500px-rgb[2]20221027132117.jpg){kind=logo}
Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease, say scientists from Dana-Farber Cancer Institute.
T-Mobile CEO is giving $4.5 million to support the Profile initiative at Dana-Farber Cancer Institute, one of the broadest and most comprehensive enterprise-level, patient-based cancer genomics projects in the world.
• Study uncovers extensive archive within adult cells of genes active at embryonic stage • Memory can be accessed under certain conditions, making it possible to reactivate fetal genes • Discovery may have major implications for regenerative medicine, cancer research
Dana-Farber researcher Cigall Kadoch, PhD, named recipient of Wachtel Cancer Research Prize
A new study shows that an innovative communication program developed by Ariadne Labs and tested at the Dana-Farber Cancer Institute resulted in more, earlier and better conversations between patients and their oncology clinicians, and led to significant reductions in emotional suffering for patients with advanced cancer.
Dana-Farber/Brigham and Women's Cancer Center announced the launch of the Young-Onset Colorectal Cancer Center. The center will provide expert, compassionate and cutting-edge care to young adult colon and rectal cancer patients with a focus on scientific discovery and research.
Dana-Farber Cancer Institute opens Center for the Prevention of Progression clinic to focus on precursor conditions in blood cancers
A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative “active surveillance” strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute.
By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery.
In a report published in Nature, however, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells.
New Executive Vice President and Chief Operating Officer named at Dana-Farber Cancer Institute
Black men diagnosed with prostate cancer classified as low risk may actually have a more aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, a new study suggests.
Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting.
Improving outcomes for patients with myeloid cancers who undergo stem cell transplantation is a focus of several studies to be presented by Dana-Farber Cancer Institute scientists at the ASH Annual Meeting.
New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting.
A new option – a combination of a standard drug and the novel agent venetoclax – has been granted accelerated approval by the Food and Drug Administration for certain AML patients after a large, multicenter phase 1 clinical trial showed the combination had “promising efficacy” and was well tolerated in older AML patients.
• $1 million in initial funding to evaluate DNA repair inhibitors in pancreatic cancer • Aim to accelerate pancreatic cancer research and improve patient outcomes for pancreatic cancer
Dana-Farber and Deerfield Management are collaborating to create the Center for Protein Degradation is to interrogate and advance a large portfolio of advanced targeted protein degrader targets while creating a next-generation protein degrader platform
Scientists have discovered a previously unknown molecular vulnerability in two rare, aggressive, and hard-to-treat types of cancer, and say it may be possible to attack this weakness with targeted drugs.
In a study published online today by the journal Immunity, scientists at Dana-Farber Cancer Institute, Harvard Medical School, Vanderbilt University and colleagues at other institutions show how machinery within immune system T cells responds to outside signals and activates the cells to attack cancerous, infected, or otherwise diseased cells.
In an ambitious effort to crack the code of several aggressive childhood cancers that lack definitive treatments, the federal Beau Biden Cancer Moonshot program has awarded grants of $2.5 million each over five years to two research teams led by scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Only three grants in total were awarded for this initiative.
Dana-Farber Cancer Institute launches a new Chinese-language website.
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?
Scientists at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.
Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American Society of Clinical Oncology.
A test that analyzes free-floating DNA in the blood may be able to detect early-stage lung cancer, a preliminary report from the ongoing Circulating Cell-Free Genome Atlas (CCGA) study suggests.
he Dana-Farber Clinical Pathways will be deployed through the Philips IntelliSpace Oncology Platform, providing clinical decision support to physicians via a patient-centric solution.
While a wide majority of oncologists do not feel informed enough about medical marijuana’s utility to make clinical recommendations, most do in fact conduct discussions on medical marijuana in the clinic and nearly half recommend it to their patients, say researchers who surveyed a population-based sample of medical oncologists.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right